{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:25:38Z","timestamp":1789626338365,"version":"build-2803163510"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Green, selective and accurate high-performance liquid chromatography (HPLC) chromatographic method is presented for simultaneous separation and quantitation of the co-prescribed drugs in chemotherapy omeprazole, ondansetron and deflazacort in spiked human plasma. An isocratic HPLC separation was performed on X Bridge C18 (4.6 \u00d7 250\u00a0mm) column with 5\u00a0\u03bcm particle size using mobile phase consisting of methanol: ammonium acetate buffer pH\u00a04 adjusted by acetic acid (60: 40, v\/v). The injection volume was 20\u03bcL with UV detection wavelength at 237\u00a0nm at room temperature. Flow rate of the mobile phase was adjusted to be 2.0\u00a0ml\/min. Dexamethasone was used as internal standard to correct the variation during sample pretreatment. FDA guidelines were followed to validate the developed method. Successful application of the developed method was revealed by simultaneous determination of omeprazole, ondansetron and deflazacort in spiked human plasma in ranges of 1\u201320, 0.1\u20138 and 0.2\u20138\u00a0\u03bcg\u00a0mL\u22121 for omeprazole, ondansetron and deflazacort, respectively. Four greenness assessment tools were used to evaluate the greenness of the developed method and the results were accepted. This method permitted the accurate simultaneous determination of the studied drugs, thus it can be used during therapeutic drug monitoring in daily clinical practice.<\/jats:p>","DOI":"10.1093\/chromsci\/bmad088","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T09:32:36Z","timestamp":1700818356000},"page":"845-853","source":"Crossref","is-referenced-by-count":3,"title":["Ecofriendly HPLC Method for Simultaneous Determination of the Co-Prescribed Drugs in Chemotherapy Omeprazole, Ondansetron and Deflazacort in Spiked Human Plasma"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-9149","authenticated-orcid":false,"given":"Fatma F","family":"Abdallah","sequence":"first","affiliation":[{"name":"Beni-Suef University Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, , Alshaheed Shehata Ahmad Hegazy St., Beni-Suef 62514 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5262-987X","authenticated-orcid":false,"given":"M","family":"Fatma","sequence":"additional","affiliation":[{"name":"Beni-Suef University Medicinal Chemistry Department, Faculty of Pharmacy, , Alshaheed Shehata Ahmad Hegazy St., Beni-Suef 62514 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"Gouda","sequence":"additional","affiliation":[{"name":"Beni-Suef University Medicinal Chemistry Department, Faculty of Pharmacy, , Alshaheed Shehata Ahmad Hegazy St., Beni-Suef 62514 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eglal A","family":"Abdelaleem","sequence":"additional","affiliation":[{"name":"Beni-Suef University Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, , Alshaheed Shehata Ahmad Hegazy St., Beni-Suef 62514 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-4960","authenticated-orcid":false,"given":"Aml A","family":"Emam","sequence":"additional","affiliation":[{"name":"Beni-Suef University Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, , Alshaheed Shehata Ahmad Hegazy St., Beni-Suef 62514 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"2024110205462949200_ref1","first-page":"89","article-title":"Pathogenesis-based treatment of chemotherapy- induced nausea and vomiting--two new agents","volume":"1","author":"Navari","year":"2003","journal-title":"The Journal of Supportive Oncology"},{"issue":"1","key":"2024110205462949200_ref2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14238\/pi58.1.2018.42-7","article-title":"The addition of omeprazole to ondansetron for treating chemotherapy-induced nausea and vomiting in pediatric cancer patients","volume":"58","author":"Simbolon","year":"2018","journal-title":"Paediatrica Indonesian"},{"issue":"2","key":"2024110205462949200_ref3","first-page":"108","article-title":"RP-HPLC method for simultaneous estimation of omeprazole and ondansetron in combined dosage forms","volume":"2","author":"Dedania","year":"2009","journal-title":"Asian Journal of Research in Chemistry"},{"issue":"12","key":"2024110205462949200_ref4","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.14233\/ajchem.2015.19347","article-title":"A new ultra performance liquid chromatographic method for determination of omeprazole in capsule dosage form","volume":"27","author":"Dermis","year":"2015","journal-title":"Asian Journal of Chemistry"},{"issue":"9","key":"2024110205462949200_ref5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/chromsci\/bmz062","article-title":"Simultaneous determination of co-administrated deflazacort, aprepitant and granisetron in dosage forms and spiked human plasma by RP-HPLC\/PAD","volume":"57","author":"Tantawy","year":"2019","journal-title":"Journal of Chromatographic Science"},{"issue":"3","key":"2024110205462949200_ref6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4103\/0250-474X.43011","article-title":"A validated HPTLC method for determination of ondansetron in combination with omeprazole or rabeprazole in solid dosage form","volume":"70","author":"Raval","year":"2008","journal-title":"Indian Journal of Pharmaceutical Sciences"},{"issue":"19","key":"2024110205462949200_ref7","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2000.18.19.3409","article-title":"Contribution of dexamethasone to control chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence","volume":"18","author":"Ioannidis","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"2024110205462949200_ref8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/oxfordjournals.annonc.a058803","article-title":"Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy- naive and previously treated patients","volume":"5","author":"Joss","year":"1994","journal-title":"Annals of Oncology"},{"key":"2024110205462949200_ref9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.1998.16.3.1174","article-title":"Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada clinical trials group","volume":"16","author":"Latreille","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"2024110205462949200_ref10","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","article-title":"Recommendations for the use of antiemetics: Evidence-based clinical practice guidelines","volume":"17","author":"Gralla","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"2024110205462949200_ref11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mdj078","article-title":"Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia Internation antiemetic consensus conference","volume":"17","author":"Roila","year":"2006","journal-title":"Annals of Oncology"},{"issue":"8","key":"2024110205462949200_ref12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1023\/A:1008471812316","article-title":"Prevention of chemotherapy- and radiotherapy-induced emesis: Results of Perugia consensus conference. Antiemetic Subcommittee of the Multinational Association of supportive Care in Cancer (MASCC)","volume":"9","author":"Perugia Consensus Conference","year":"1998","journal-title":"Annals of Oncology"},{"issue":"42","key":"2024110205462949200_ref13","doi-asserted-by":"crossref","first-page":"18419","DOI":"10.1039\/D0NJ03418E","article-title":"Determination of the correlation between the structure and dynamics of Deflazacort by solid state NMR measurements","volume":"44","author":"Dey","year":"2020","journal-title":"New Journal of Chemistry"},{"issue":"2","key":"2024110205462949200_ref14","first-page":"762","article-title":"Dual wavelength methods for simultaneous estimation of omeprazole and Cinitapride in combined capsule dosage form","volume":"3","author":"Jagani","year":"2012","journal-title":"Int. J. Res. Pharm. Sci."},{"key":"2024110205462949200_ref15","first-page":"2153","article-title":"Development and validation of UV spectrophotometric method for simultaneous equation method for estimation omeprazole and aspirin tablet dosage form","volume":"11","author":"Chaudhry","year":"2020","journal-title":"Pharm. Ana. Acta"},{"issue":"8","key":"2024110205462949200_ref16","first-page":"2573","article-title":"Development and validation of UV spectrophotometric method for the simultaneous equation method for omeprazole and Domperidone","volume":"1","author":"Javali","year":"2017","journal-title":"Global J. Pharmacy Pharm. Sci."},{"key":"2024110205462949200_ref17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/jaoac\/93.3.787","article-title":"Stability indicating HPTLC method for quantitative determination of omeprazole capsule dosage form","volume":"93","author":"Jha","year":"2010","journal-title":"AOAC J.Int."},{"key":"2024110205462949200_ref18","article-title":"HPTLC for simultaneous determination of Cinitapride and omeprazole in pharmaceutical dosage form","author":"Chauhan","year":"2012","journal-title":"Pharm Ana. And Quality Assurance"},{"key":"2024110205462949200_ref19","first-page":"3397","article-title":"Development validation new analytical estimation of Drotavereine and omeprazole by HPTLC method","volume":"11","author":"Kothapalli","year":"2017","journal-title":"Arabian Journal of Chemistry"},{"issue":"1","key":"2024110205462949200_ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.11648\/j.ajche.20180601.11","article-title":"Development and validation for RP-HPLC methods for estimation of omeprazole capsule","volume":"6","author":"Ali","year":"2018","journal-title":"American J. Chem. Eng."},{"issue":"1","key":"2024110205462949200_ref21","first-page":"275","article-title":"RP-HPLC for development and validation of omeprazole in bulk and pharmaceutical dosage form","volume":"11","author":"Rajan","year":"2018","journal-title":"Asian J. Res. Chem."},{"key":"2024110205462949200_ref22","first-page":"5397","article-title":"Development and validation new analytical estimation of Drotavereine hydrochlorides and omeprazole by RP-HPLC method","volume":"16","author":"SharmaS","year":"2017","journal-title":"Arabian Journal of Chemistry"},{"issue":"5","key":"2024110205462949200_ref23","first-page":"333","article-title":"Development and validation of simple UV-visible spectrophotometry method quantization of ondansetron hydrochloride in solid dosage formulation","volume":"9","author":"Jain","year":"2017","journal-title":"International Journal of Pharmaceutical Sciences and Research"},{"issue":"2","key":"2024110205462949200_ref24","first-page":"83","article-title":"UV-spectrophotometric method development and validation quantitative estimation of ondansetron hydrochloride","volume":"5","author":"Savale","year":"2017","journal-title":"Asian J. Res. Chem. Pharm. Sci."},{"issue":"6","key":"2024110205462949200_ref25","first-page":"678","article-title":"Method development and validation of ondansetron in bulk and pharmaceutical dosage form by UV spectrophotometry","volume":"7","author":"Sruthi","year":"2019","journal-title":"Int. J. Med. Pharm. Res."},{"key":"2024110205462949200_ref26","first-page":"766","article-title":"Stability indicating RP-HPLC method for determination ondansetron","volume":"10","author":"Annapurna","year":"2017","journal-title":"Journal of Chemical and Pharmaceutical Sciences"},{"issue":"2","key":"2024110205462949200_ref27","first-page":"450","article-title":"Development and validation of ondansetron hydrochloride in pharmaceutical dosage form by RP-HPLC method","volume":"2","author":"Deshmukh","year":"2015","journal-title":"Int. J. Adv. Sci. Eng. Techno."},{"issue":"1","key":"2024110205462949200_ref28","first-page":"584","article-title":"Development and validation of stability indicating HPLC method for estimation of ondansetron hydrochloride","volume":"5","author":"Gandhi","year":"2018","journal-title":"Indo Am. J. Pharm. Sci."},{"issue":"10","key":"2024110205462949200_ref29","first-page":"827","article-title":"Development and validation simultaneous estimation of omeprazole and ondansetron hydrochloride by HPTLC method","volume":"2","author":"Khatal","year":"2014","journal-title":"Research Article"},{"issue":"6","key":"2024110205462949200_ref30","first-page":"787","article-title":"Simultaneous spectrophotometric estimation of omeprazole and ondansetron hydrochloride by first order derivative spectroscopy","volume":"5","author":"Kolte","year":"2012","journal-title":"Asian J. Res. Chem."},{"key":"2024110205462949200_ref31","first-page":"4423","article-title":"Validated spectrophotometric methods for determination of deflazacort in tablet dosage form","volume":"2231","author":"Ambalal","year":"2011","journal-title":"Asian J Pharm Life Sci"},{"issue":"1","key":"2024110205462949200_ref32","first-page":"140","article-title":"Development and validation of high performance liquid chromatographic method for estimation of deflazacort in pharmaceutical formulation","volume":"4","author":"Chougule","year":"2011","journal-title":"Asian J Res Chem"},{"issue":"9\u201310","key":"2024110205462949200_ref33","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1365\/s10337-007-0205-y","article-title":"Development and validation of a reversed-phase HPLC method for the determination of deflazacort in pharmaceutical dosage forms","volume":"65","author":"Corr\u00eaa","year":"2007","journal-title":"Chromatographia"},{"issue":"15","key":"2024110205462949200_ref34","first-page":"538","article-title":"UV-spectroscopy method development and validation of deflazacort and tamsulosin hydrochloride in combined dosage form","volume":"7","author":"Rupapara","year":"2018","journal-title":"World Journal of Pharmaceutical Research"},{"issue":"2","key":"2024110205462949200_ref35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1556\/1006.2019.32.2.9","article-title":"High-performance thin-layer chromatography for the simultaneous determination of co-administrated granisetron, aprepitant, and deflazacort used with chemotherapy: Application onto dosage forms and spiked plasma by liquid\u2013liquid extraction","volume":"32","author":"Yehia","year":"2019","journal-title":"J Planar Chromatograph Modern TLC"},{"issue":"2","key":"2024110205462949200_ref36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/2229-4708.84450","article-title":"Determination of deflazacort in human plasma by liquid chromatography-mass spectrometry after liquid-liquid extraction and its application in human pharmacokinetics studies","volume":"2","author":"Selvadurai","year":"2011","journal-title":"Pharm Method"},{"issue":"13","key":"2024110205462949200_ref37","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1081\/JLC-120022399","article-title":"Drug dissolution studies and determination of deflazacort in pharmaceutical formulations and human serum samples by RP-HPLC","volume":"26","author":"\u00d6zkan","year":"2003","journal-title":"J Liq Chrom Relat Tech"},{"issue":"5","key":"2024110205462949200_ref38","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00216-007-1802-1","article-title":"A screening method for the detection of synthetic glucocorticosteroids in human urine by liquid chromatography\u2013mass spectrometry based on class-characteristic fragmentation pathways","volume":"390","author":"Mazzarino","year":"2008","journal-title":"Analytical and Bioanalytical Chemistry"},{"issue":"2","key":"2024110205462949200_ref39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1590\/S1984-82502010000200015","article-title":"Spectrophotometric and HPLC determination of deflazacort in pharmaceutical dosage forms","volume":"46","author":"Scremin","year":"2010","journal-title":"Brazilian Journal of Pharmaceutical Sciences"},{"issue":"2","key":"2024110205462949200_ref40","first-page":"75","article-title":"LC-MS\/MS method for the quantification of deflazacort metabolite in human plasma: Development, validation and application to a pharmacokinetic study","volume":"3","author":"Karthikeyan","year":"2013","journal-title":"J Drug Deliv Therapeut"},{"issue":"7","key":"2024110205462949200_ref41","first-page":"127","article-title":"Development and validation of spectrofluorimetric method for estimation of deflazacort in tablets","volume":"1","author":"Patel","year":"2011","journal-title":"J Appl Pharm Sci"},{"issue":"07","key":"2024110205462949200_ref42","first-page":"94","article-title":"High performance thin layer chromatographic method for estimation of deflazacort in tablet","volume":"1","author":"Patel","year":"2011","journal-title":"J Appl Pharm Sci"},{"key":"2024110205462949200_ref43","article-title":"PRILOSEC (omeprazole) [package insert]","author":"AstraZeneca Pharmaceuticals"},{"key":"2024110205462949200_ref44","article-title":"EMFLAZA (deflazacort) [package insert]","author":"Marathon Pharmaceuticals"},{"key":"2024110205462949200_ref45","volume-title":"ZOFRAN\u00ae (ondansetron hydrochloride) [package insert]","author":"GlaxoSmithKline"},{"key":"2024110205462949200_ref46","volume-title":"Bioanalytical method validation guidance for industry","author":"U.S","year":"2018"},{"issue":"5","key":"2024110205462949200_ref47","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5343","article-title":"US FDA\u2013validated TLC method with four greenness assessment evaluations for simultaneous determination of prednisolone and esomeprazole in spiked human plasma","volume":"36","author":"Abdelhamid","year":"2022","journal-title":"Biomedical Chromatography"},{"key":"2024110205462949200_ref48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","article-title":"Analytical eco-scale for assessing the greenness of analytical procedures","volume":"37","author":"Ga\u0142uszka","year":"2012","journal-title":"TrAC Trends in Analytical Chemestry"},{"key":"2024110205462949200_ref49","doi-asserted-by":"crossref","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","article-title":"AGREE\u2014Analytical GREEnness metric approach and software","volume":"92","author":"Pena-Pereira","year":"2020","journal-title":"Analytical Chemistry"},{"key":"2024110205462949200_ref50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","article-title":"A new tool for the evaluation of the analytical procedure: Green analytical procedure index","volume":"181","author":"P\u0142otka-Wasylka","year":"2018","journal-title":"Talanta"},{"key":"2024110205462949200_ref51","author":"The United States Pharmacopeia","year":"2011"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/62\/9\/845\/60290764\/bmad088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/62\/9\/845\/60290764\/bmad088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T05:46:47Z","timestamp":1730526407000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/62\/9\/845\/7444765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,11,23]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmad088","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2023,11,23]]}}}